Nakashima A, Yamamoto I, Kobayashi A, Kimura K, Yaginuma T, Nishio S, Kato K, Kawai R, Horino T, Ohkido I, Yokoo T. Active vitamin D analog and SARS-CoV-2 IgG after BNT162b2 vaccination in patients with hemodialysis.
Ther Apher Dial 2024. [PMID:
38504452 DOI:
10.1111/1744-9987.14121]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 02/07/2024] [Accepted: 02/21/2024] [Indexed: 03/21/2024]
Abstract
INTRODUCTION
Vaccination is the effective strategy for coronavirus disease 2019 (COVID-19). However, few studies have investigated the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig)G and vitamin D.
METHODS
This study aimed to investigate the association between SARS-CoV-2 IgG and active vitamin D analogs in hemodialysis patients. Blood samples were collected four times: before vaccination and 30, 60, and 90 days after vaccination, BNT162b2 (Pfizer©).
RESULTS
A total of 418 patients were enrolled. The mean age was 71.1 ± 12 years. Almost two thirds of the patients were prescribed active vitamin D analogs. The distribution of SARS-CoV-2 IgG before vaccination was 235 (93-454) AU/mL. After multiple regression analyses, active vitamin D analog use was found to be associated with higher SARS-CoV-2 IgG levels from prevaccination to 90 days postvaccination.
CONCLUSION
This study demonstrated an association between higher SARS-CoV-2 IgG and active vitamin D analog use in hemodialysis patients.
CLINICAL TRIAL REGISTRATION
The study information was registered in the UMIN-CTR (UMIN 000046906).
Collapse